|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
23
|
|
pubmed:dateCreated |
2002-11-6
|
|
pubmed:abstractText |
A series of novel, highly potent alpha(v)beta(3) receptor antagonists with favorable pharmacokinetic profiles has been identified. In this series of antagonists, 2-aryl beta-amino acids function as potent aspartic acid replacements.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
pubmed-author:BarrishAndreaA,
pubmed-author:BrashearKaren MKM,
pubmed-author:ColemanPaul JPJ,
pubmed-author:DugganMark EME,
pubmed-author:Fernandez-MetzlerCarmenC,
pubmed-author:HartmanGeorge DGD,
pubmed-author:HomnickCarl FCF,
pubmed-author:HuntCecilia ACA,
pubmed-author:HutchinsonJohn HJH,
pubmed-author:KucerBrian TBT,
pubmed-author:LeuChi-TaiCT,
pubmed-author:PrueksaritanontThomayantT,
pubmed-author:RodanGideon AGA,
pubmed-author:RodanSevgi BSB
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
12
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
3483-6
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12419389-Amino Acids,
pubmed-meshheading:12419389-Animals,
pubmed-meshheading:12419389-Aspartic Acid,
pubmed-meshheading:12419389-Biomimetic Materials,
pubmed-meshheading:12419389-Dogs,
pubmed-meshheading:12419389-Drug Evaluation, Preclinical,
pubmed-meshheading:12419389-Esters,
pubmed-meshheading:12419389-Humans,
pubmed-meshheading:12419389-Inhibitory Concentration 50,
pubmed-meshheading:12419389-Oligopeptides,
pubmed-meshheading:12419389-Protein Binding,
pubmed-meshheading:12419389-Receptors, Vitronectin,
pubmed-meshheading:12419389-Structure-Activity Relationship
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Non-peptide alpha(v)beta(3) antagonists. Part 5: identification of potent RGD mimetics incorporating 2-aryl beta-amino acids as aspartic acid replacements.
|
|
pubmed:affiliation |
Department of Medicinal Chemistry, Merck Research Laboratories, West Point, PA 19486, USA. karen_brashear@merck.com
|
|
pubmed:publicationType |
Journal Article
|
